AAIC 2025 Abstract·9 JanImplementation of task‐based fMRI in TRAILBLAZER‐ALZ 6 Phase 3b study: Methodological considerationsTrial in peopleBiomarkersPaper
AAIC 2025 Abstract·23 DecImplementation of task‐based fMRI in TRAILBLAZER‐ALZ 6 Phase 3b study: Methodological considerationsTrial in peopleBiomarkersPaper
AAIC 2025 Abstract·23 DecComparable cumulative exposure and amyloid reduction following donanemab standard and modified titration dosing in participants with early symptomatic Alzheimer’s disease from TRAILBLAZER‐ALZ 6Trial in peopleInterventionsPaper